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Expression of Insulinlike
Growth Factor (IGF) and
IGF-Binding Protein Genes in
Human Lung Tumor Cell Lines
J. G. Reeve* A. Brinkman,
S. Hughes, J. Mitchell,
J. Schwander, N. M. Bleehen
Background: The presence of multiple,
low-molecular-weight, insulinlike growth
factor (IGF)-binding proteins in lung
tumor cell-conditioned medium and
lung cancer patient serum has been
recently reported. Purpose: To begin to
elucidate the genetic basis for these ob-
servations, the present study examines
the expression by lung tumor cell lines
of three IGF-binding protein genes,
namely, IGFBP-1, IGFBP-2, and
IGFBP-3. Since IGF-binding proteins
are thought to modulate the biologic
action of the IGFs, the relationship be-
tween the expression of IGF-binding
protein genes and the genes encoding
IGF-I and IGF-II also has been inves-
tigated. Methods: Gene expression was
studied in four small-cell lung cancer
(SCLC) and three non-small-cell lung
cancer (NSCLC) cell lines using North-
ern blot analysis and reverse transcriptase
polymerase chain reaction (RT-PCR) for
IGFBP-1. Results: IGFBP-1 gene ex-
pression was detected by Northern blot
analysis in one NSCLC cell line only.
However, RT-PCR revealed that the
IGFBP-1 gene was expressed in all four
SCLC cell lines and in two of the three
NSCLC lines. Northern blot analysis of
IGFBP-2 gene expression demon-
strated that all lung tumor cell lines ex-
pressed this gene. A low level of
IGFBP-3 gene expression was detected
in one SCLC cell line and in all three
NSCLC cell lines. All lung tumor cell
lines expressed the IGF-II gene as
determined by Northern blot analysis.
In marked contrast, none of the lines
showed evidence of IGF-I gene expres-
sion using this method. However, RT-
PCR revealed a low level of IGF-I gene
expression in one SCLC and one
NSCLC cell line only. Conclusions:
These observations indicate 1) that
IGF-binding proteins secreted by lung
tumors are encoded by at least three
different genes; 2) that there may be a
close association between IGF-II and
IGFBP-2 gene expression, such that,
where there is production of IGF-II,
IGFBP-2 is the principal BP; and 3)
that the IGF-II gene is more widely ex-
pressed than the IGF-I gene in human
lung tumor cell lines. [J Natl Cancer
Institute 84:628-634,1992]
An increasing number of proteins with
insulinlike growth factor (IGF)-binding
characteristics have been isolated from
various body fluids, tissue extracts, and
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cell lines (1). On the basis of extensive
protein and complementary DNA
(cDNA) sequencing studies, these pro-
teins have been classified (2) into six dis-
tinct groups. IGFBP-1, also named
placental protein 12 (ppl2) (3), IBP-1 (4),
BP-25 (5), BP-28 (6), and alpha pregnan-
cy-associated endometrial globulin (7),
has been purified from amniotic fluid and
several other sources. Its cloned cDNA
sequence predicts a molecular mass of 25
kd, and expression of the cDNA encoding
IGFBP-1 in COS cells results in the syn-
thesis of protein with a relative molecular
mass (MT) of 30 kd on nonreduced sodi-
um dodecyl sulfate (SDS)-polyacryla-
mide gel electrophoresis (PAGE) (4).
IGFBP-2 (8) is the human homologue of
a protein isolated from rat BRL-3a cells
(9) and has been isolated from human
serum (10). The cDNA sequence of the
human protein predicts a molecular mass
of 31 kd; under nonreducing conditions,
the expressed protein has an Mr of 36 kd
(8). IGFBP-3, also known as BP-53 (//),
is a growth hormone-dependent protein,
originally purified from human plasma.
On nonreduced SDS-PAGE, the protein
appears as a glycoprotein doublet consist-
ing of a major 53-kd and a minor 47-kd
component (//). The cDNA for this
protein predicts a molecular mass of 28
kd for the nonglycosylated protein (12).
IGFBP-4, isolated from human osteoblas-
toma- (13) and prostatic carcinoma- (14)
conditioned media and human serum
(10), has a predicted molecular mass of
22 kd and migrates as a 28- to 30-kd IGF-
binding protein on nonreduced gels. A
further IGF-binding protein, IGFBP-5,
isolated from cerebrospinal fluid (15) and
human serum (10), has a predicted molec-
ular mass of 26 kd for the mature protein
and an MT of 24 kd for the nonglycosy-
lated protein. Finally, a sixth IGF-binding
protein, 1GFBP-6, has been purified re-
cently from pig ovarian follicular fluid,
and cDNA clones encoding rat and hu-
man IGFBP-6 have also been isolated and
characterized (16). All six IGF-binding
proteins are distinct from the type I and
type II receptors for IGFs; importantly,
stimulatory (1,17-19) and/or inhibitory
(1,20,21) effects on cell growth have
been demonstrated for certain IGF-bind-
ing proteins.
Recently, multiple IGF-binding pro-
teins have been shown to be secreted by
human lung tumor cells both in vitro
(22,23) and in vivo (23). These proteins,
under nonreducing conditions, range in
size from 12 kd to 30 kd and may be en-
coded by one or more of the aforemen-
tioned genes. To determine whether lung
tumor cells secrete multiple different
IGF-binding proteins, the present study
examines the expression of the IGFBP-1,
IGFBP-2, and IGFBP-3 genes in a panel
of small-cell lung cancer (SCLC) and
non-small-cell lung cancer (NSCLC) cell
lines and examines the relationship be-
tween IGF-binding protein gene expres-
sion and expression of the genes en-
coding IGF-I and IGF-II.
Materials and Methods
Cell Lines
Full details of the derivation and char-
acterization of SCLC cell lines COR-L47,
COR-L51, and COR-L88 and large-cell
lung cancer cell line COR-L23 have been
described (24). The classic SCLC cell
line NCI-H69 was donated by Drs. D.
Carney and A. Gazdar (National Cancer
Institute Navy Medical Oncology Branch,
Bethesda, Md.). The squamous cell lung
carcinoma cell line BEN and the lung
adenocarcinoma cell line MOR were
from Dr. M. Ellison (Ludwig Institute,
Sutton, Surrey, England). All cell lines
were grown in RPMI-1640 medium sup-
plemented with 10% fetal calf serum
(both medium and serum from GIBCO
BRL, Paisley, Scotland).
RNA Preparation
Cells in logarithmic phase of growth
were collected by centrifugation at 300g
for 10 minutes and suspended in 100 \xh
of medium. A solution containing 6.0 M
guanidine hydrochloride and 0.2 M
sodium acetate (pH 5.5) was added to the
cells (20 mL per 5 x 107 cells), and the
. DNA was sheared by vigorous homogeni-
zation in a Virtis homogenizer (Virtis
Co., Gardiner, N.Y.). RNA was pre-
cipitated by the addition of a half volume
of 95% ethanol followed by incubation at
-20 °C overnight. The pelleted precipitate
was dissolved in a solution containing 7.0
M urea, 0.35 M NaCl, 50 mM Tris (pH
7.5), 1 mM EDTA, and 0.2% SDS and
then was extracted once with phenol-
chloroform. RNA was precipitated from
the aqueous phase using two volumes of
ethanol, washed with 70% ethanol, air
dried, and dissolved in sterile, double-dis-
tilled water.
Poly(A)+ RNA was prepared from total
RNA using a messenger RNA (mRNA)
purification kit (Pharmacia LKB Biotech-
nology Inc., Piscataway, N.J.).
Northern Blot Analysis
Five micrograms of poly(A)+ RNA in
10 mM sodium phosphate buffer (pH 7.0)
was denatured in 1.0M glyoxal for 1 hour
at 50 °C. The RNA was electrophoresed
in a 1.4% agarose gel in 10 mM sodium
phosphate buffer and was transferred by
Northern blotting to nylon filters. After
treatment for 2 minutes with UV light,
the nylon filters were baked at 80 °C for 2
hours before hybridization.
The IGFBP-3 (12) and the IGF-I and
IGF-II cDNA probes (25) were supplied
by Genentech Inc., San Francisco, Calif.,
and by Dr. G. Bell, Howard Hughes
Medical Institute, Chicago, 111., respec-
tively. The IGFBP-1 (4) and the IGFBP-2
(8) cDNAs, both cloned into the vector
PTZ19 (Pharmacia LKB Biotechnology
Inc.), the IGFBP-3 cDNA, cloned into the
pUC119 vector (12), and the IGF-I and
IGF-II cDNAs, cloned into the pKT218
vector (Pharmacia LKB Biotechnology
Inc.), were separated from their vectors
by treatment with EcoRl followed by
agarose gel electrophoresis. The £coRI
fragments, still in the gel slice, were radio-
labeled by transcribing the fragments
using mixed oligonucleotides to initiate
transcription. The radiolabeled probes
were separated from unincorporated
nucleotide triphosphates using Sephadex
G50 (Pharmacia LKB Biotechnology,
Inc.) and boiled for 3 minutes before use.
A mouse p actin probe, PRT3 (donated
by Dr. John Rogers, Laboratory of
Molecular Biology, Medical Research
Council), was similarly labeled to con-
firm equal loading of RNA.
The labeled probe, at a concentration
of 106 counts per minute per milliliter,
was hybridized to the filter in 1 M NaCl
and 0.1 M trisodium citrate (6x SSC), 5%
dextran sulfate, 0.02% Ficoll, 0.02%
bovine serum albumin, 0.02% polyvinyl
pyrrolidone, 0.1% SDS, and 150 ng/mL
sonicated salmon sperm DNA at 65 °C
for 18 hours. The filter was washed with
6x SSC and 0.1% SDS at 65 °C to
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remove unhybridized probe prior to
autoradiography.
Reverse Transcriptase Polymerase
Chain Reaction Analysis of IGFBP-1
and IGF-I Gene Expression
Synthetic oligonucleotides, designed
on the basis of the nucleotide sequence of
the mRNA encoding IGFBP-1 and IGF-I,
were synthesized using an Applied Bio-
systems 380 DNA Synthesizer (Applied
Biosystems, Warrington, England). The
sequences of the IGFBP-1 specific pri-
mers were the following:
(B1) 5'GCTCCCCATGCTGCAGAGG-
CAGGG3' corresponding to nucleotides
386-409.
(B2) 5'TACATTAAAATACATCTGG-
CAGTT3' complementary to nucleotides
823-800.
The 437-base-pair (bp) amplification
product is unique to IGFBP-1.
The sequences of the primers used for
reverse transcriptase polymerase chain
reaction (RT-PCR) analysis of IGF-I gene
expression were the following:
(IG-1) 5'TCTTGAAGGTGAAGAT-
GCACACCA3' corresponding to
nucleotides 238-261.
(IG-2) 5'AGCGAGCTGACTTGGCA-
GGCTTGA3' complementary to
nucleotides 540-517.
The 302-bp amplification product is com-
mon to IGF-IA and IGF-IB.
Ten micrograms of total RNA was
reversed transcribed into first-strand
cDNA by addition of 5 [ih 0.1 M dithio-
threitol, 2.5 \iL 5 nW deoxyribo-
nucleoside triphosphate (dNTP)
(Pharmacia LKB, Milton Keynes,
England), 20 pmol of either oligo-
nucleotide B2 or IG-2, and 5 (iL 5x
reverse transcriptase buffer (500 xnM Tris
[pH 8.3], 60 m/W MgCl2, and 400 mA/ KC1).
After heating for 10 minutes at 70 °C,
the reaction mixture was cooled to 25 °C,
and 2 units of avian myeloblastosis virus
reverse transcriptase (Anglian Biotec Ltd.,
Colchester, England) were added. Fol-
lowing incubation at 42 °C for 1 hour, a
5-|iL aliquot of first-strand cDNA was
added to 20 pmol of either oligonucleo-
tide primers Bl and B2 or IG-1 and IG-2,
5 iiL 5 mM dNTP, and 5 nL lOx Ther-
mus aquaticus (Taq) polymerase buffer—
0.67 mM Tris (pH 8.8), 9.17 M
(NH4)2SO4, 0.1 M MgCl2, 0.1 M
bromomercaptoethanol, and 2 mg/mL
gelatin—in a total volume of 50 |j.L. Two
units of Taq polymerase (ILS Ltd., Lon-
don, England) were added, and amplifica-
tion (35 cycles) was performed using a
PHC-1 automated cycler (Techne Ltd.,
Duxford, England). Annealing was for 2
minutes at 55 °C, polymerization was at
72 °C for 3 minutes, and denaturation was
at 95 °C for 1 minute. Forty microliters of
the reaction mixture was then electro-
phoresed on 1.4% agarose gels in the
presence of ethidium bromide. Amplified
products were detected by UV light trans-
illumination and by autoradiography fol-
lowing Southern blotting and hybridiza-
tion with either IGFBP-1 cDNA or IGF-I
cDNA.
Results
IGFBP-1 Gene Expression
Using a 32P-labeled £coRI fragment
derived from cDNA clone W85 as a
probe, a single transcript of approximate-
ly 1.5 kb was detected in the squamous
cell lung carcinoma cell line BEN only
(data not shown). However, Southern blot
analysis of amplification products pro-
duced by RT-PCR (Fig. 1) revealed that
the IGFBP-1 gene was expressed in all
SCLC cell lines, the BEN cell line, and
the large-cell lung carcinoma cell line
COR-L23, as evidenced for each cell line
by the hybridization of an amplification
product having the expected molecular
mass of 437 bp to the radiolabeled
IGFBP-1 cDNA probe. Only the lung
adenocarcinoma cell line MOR failed to
show IGFBP-1 gene expression.
IGFBP-2 Gene Expression
Fig. 2 (panel a) shows that IGFBP-2
gene expression was detected by North-
ern blot analysis in all SCLC and NSCLC
cell lines. Two transcripts were present in
all cell lines: a 4-kb and a 1.4-kb species.
The 4-kb species could not be removed
by washing filters in 0.1 x SSC and 0.1%
SDS. Fig. 2 (panel b) shows hybridization
of mRNAs with the mouse (3 actin cDNA
probe.
IGFBP-3 Gene Expression
A single 2.5-kb IGFBP-3 gene trans-
cript was detected by Northern blot
analysis in one of the four SCLC cell
lines and in all NSCLC cell lines studied
(Fig. 3, panel a). In addition, a smaller
mRNA species was detected in the MOR
cell line. Detection of IGFBP-3 gene ex-
pression required long exposure times of
up to 10 days. Hybridization of lung
tumor mRNAs to the mouse (3 actin probe
is shown in Fig. 3 (panel b). The apparent
absence of IGFBP-3 transcripts in SCLC
cell lines NCI-H69, COR-L47, and COR-
L88 was investigated further using RT-
PCR. No evidence of IGFBP-3 gene
expression in these cell lines was ob-
served using this method (data not
shown).
IGF-I and IGF-II Gene Expression
The IGF-I cDNA probe used in this
study hybridized to 1.1-kb and 6.3-kb
transcripts in human liver. However, no
evidence of IGF-I gene expression was
obtained by Northern blot analysis in any
of the lung tumor cell lines examined
(data not shown). The expression of the
IGF-I gene was investigated further using
RT-PCR. Fig. 4 shows that, with this
method, amplification products of the ex-
pected size were detected in one of the
four SCLC and in one of the three NSCLC
cell lines.
Fig. 5 shows Northern blot analysis of
IGF-II gene expression and demonstrates
the presence of IGF-II gene transcripts in
all lung tumor cell lines examined. A 5.3-
kb transcript was detected in liver
poly(A)+ RNA. Three transcripts, 3.5 kb,
4.8 kb, and 6 kb, were detected in SCLC
cell lines NCI-H69 and COR-L47 and in
the lung adenocarcinoma cell line MOR.
Only the 6-kb and 4.8-kb transcripts were
present in COR-L51. A weak but detec-
table 4.8-kb transcript only was observed
in NSCLC cell lines COR-L23 and BEN.
SCLC cell line COR-L88 failed to show
IGF-II gene expression.
Discussion
We have shown previously that SCLC
and NSCLC cell lines produce multiple
low-molecular-weight IGFBPs and that
sera from lung cancer patients contain
elevated levels of these proteins (25). Af-
finity cross-linking studies indicated that
lung tumor cells may secrete up to four
different molecular-weight species, in-
cluding 30-kd, 28-kd, 25-kd, and 12-kd
proteins. The present study has inves-
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Fig. 1. Detection of IGFBP-1 gene expression in SCLC and NSCLC cell lines by RT-PCR and Southern
blotting, followed by hybridization with a 1.2-kb radiolabeled IGFBP-1 cDNA probe (clone w85).
Fig. 2. Northern blot analysis of IGFBP-2 gene expression in SCLC and NSCLC cell lines (panel a). Blots
were probed with a 1.5-kb fragment containing approximately 60 bp of 5' untranslated and approximately
470 bp of 3' untranslated regions. In all cell lines, 4.0-kb and 1.4-kb IGFBP-2 transcripts are present. The
actin signal for each cell line is shown in panel b.
tigated the expression of three genes en-
coding IGFBPs, namely, IGFBP-1,
IGFBP-2, and IGFBP-3, in these cells
and demonstrates the concomitant expres-
sion of two of these genes in four of
seven cell lines and of all three genes in
the remaining three cell lines studied.
IGFBP-1 gene expression, though un-
detectable in most cell lines by Northern
blot analysis, does occur in most SCLC
and NSCLC lung tumor cells. This ex-
pression is evidenced by hybridization of
low-molecular-weight amplification prod-
ucts generated from enzymatic amplifica-
tion from IGFBP-1 mRNA via RT-PCR,
with the IGFBP-1 cDNA probe. Expres-
sion of this gene correlates with the secre-
tion of a 25-kd IGFBP by lung tumor cell
lines, as indicated by the observation that
this protein is secreted by all cell lines ex-
cept MOR—the only line showing no
IGFBP-1 gene expression. IGFBP-2 gene
expression was readily detected by North-
ern blot analysis in all cell lines ex-
amined, and pilot studies using an
IGFBP-2-specific radioimmunoassay con-
firm the secretion of this protein by the
lung tumor cell lines studied here. Fi-
nally, all NSCLC cell lines and one of the
four SCLC lines showed IGFBP-3 gene
expression. The findings of the present
study are in marked contrast to those of a
recent report in which IGFBP-2 gene ex-
pression only was detected in lung tumor
cell lines (26). Detection of IGFBP-1
gene expression in the present study is at-
tributable to the use of a sensitive RT-
PCR method, and detection of IGFBP-3
transcripts is attributable to the use of
greater amounts of poly(A)+ RNA than
those used in the Northern blot analyses
of the earlier study.
The findings of the present study indi-
cate that, of the three IGF-binding pro-
teins studied, IGFBP-2 is the principal
one produced by lung tumor cell lines.
The marked differences in the relative
levels of IGFBP-1, IGFBP-2, and IGFBP-
3 gene expression detected in the various
lines examined may reflect differences in
IGF-binding protein gene activation, vari-
ation in mRNA stabilities, or expression
of the IGFBP-1 and IGFBP-3 genes in a
subset of cells only. A number of factors
have been shown to influence the expres-
sion of IGF-binding protein genes, in-
cluding insulin which decreases IGFBP-2
gene expression (27), growth hormone
which decreases transcription of the
IGFBP-1 gene (28), and dexamethasone
which increases both IGFBP-1 (29) and
IGFBP-3 (30) mRNAs in hepatocytes.
Studies are in progress to identify factors
involved in the hormonal regulation of tu-
mor-derived IGF-binding protein produc-
tion.
The sizes of the IGFBP-1 and IGFBP-3
gene transcripts reported here for lung
tumor cells are consistent with those
detected in human liver (4,12). In con-
trast, normal adult liver contains only a
1.4-kb IGFBP-2 mRNA, whereas most
lung tumor cell lines contained this
transcript and a 4-kb mRNA. We have
recently detected this transcript in fetal
lung fibroblasts (Reeve JG: unpublished
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Fig. 3. Northern blot analysis of IGFBP-3 gene expression in SCLC and NSCLC cell lines (panel a). Blots
were probed with a 2.5-kb fragment including the full coding region of human IGFBP-3. A 2.5-kb transcript
is present in only one SCLC cell line. In contrast, all three NSCLC cell lines express the IGFBP-3 gene. A
2.0-kb transcript is also detected in the lung adenocarcinoma cell line MOR. The actin signal for each cell
line is given in panel b.
Fig. 4. Detection of IGF-I gene expression in lung tumor cell lines by RT-PCR followed by Southern blotting
and hybridization to the 0.66-kb phigf-I cDNA probe. Amplification products having the expected size of
302 bp were detected in the SCLC cell line NCI-H69 and the lung adenocarcinoma cell line MOR only.
data), and it is also present in fetal liver
and in the HepG2 and the WRL-68
embryonic liver lines {31). In the liver,
the presence of the 4-kb transcript ap-
pears to be inversely related to the degree
of differentiation, in that adult liver con-
tains only the mature 1.4-kb mRNA, fetal
liver contains both the 1.4-kb and the 4-
kb transcripts, but cultured WRL-68
embryonic liver cells contain only the 4-
kb mRNA. The presence of the 4-kb
transcript in human lung tumor cells and
fetal lung fibroblasts may indicate that
the presence of this transcript is also dif-
ferentiation related in the lung. Studies
are in progress to investigate the relative
amounts of these two transcripts in a
variety of normal fetal and adult tissues.
Although the biological significance of
IGF-binding protein production by lung
tumor cells is not known at this time, a
number of studies have shown that these
proteins can modulate cellular responses
to IGF stimulation. IGF-binding proteins
have been shown to inhibit the effects of
IGF-I and IGF-II on fibroblast DNA syn-
thesis (20,21), to increase the binding of
IGF-I to its receptor (32), to potentiate
markedly the replication of human, mouse,
and chicken fibroblasts in response to
IGF-I stimulation (17), and to enhance
the cellular DNA synthesis response of
cultured porcine aortic smooth muscle
cells to IGF-I (19). Given that both IGF-I
and IGF-II have been shown to promote
the proliferation of SCLC cells in vitro
(33,34), IGF-binding proteins may regu-
late the mitogenic action of the IGFs in
these cells.
A number of studies have reported the
secretion of immunoreactive IGF-I (2333)
and the presence of IGF-I receptors (22,
34) in SCLC cell lines. Such observations,
together with the mitogenic responsiveness
of these cells to IGF-I stimulation and the
growth-inhibitory effects of antibodies to
the IGF-I receptor, have led to the con-
clusion that IGF-I is an important auto-
crine growth factor for SCLC (33-36).
However, the present study is the first to
examine the expression of the IGF-I gene
in SCLC cell lines and shows that the
majority of SCLC cell lines studied failed
to express the IGF-I gene as determined
by RT-PCR, perhaps challenging the im-
portance of this peptide in the autocrine
growth of SCLC. This finding, as well as
the low level of IGF-I gene expression
found in the only positive SCLC cell line,
is surprising, given that several of the cell
lines investigated have been shown to
secrete low levels of immunoreactive
IGF-I (25). However, the antiserum used
to determine IGF-I secretion showed 3%
cross-reactivity with IGF-II. Given the
observed expression of the IGF-II gene in
all the lines studied, secretion of IGF-II,
and not IGF-I, seems more likely.
Together with the observation that ex-
ogenous IGF-II promotes SCLC cell
proliferation (33) and stimulates DNA
synthesis in NSCLC cell lines (Reeve JG,
Schwander J, Bleehen NM: manuscript
submitted for publication), the findings of
the present study support the contention
that IGF-II may be more widely involved
in the autocrine growth of lung tumors
than IGF-I.
IGF-II gene expression in lung tumor
cell lines is particularly interesting, given
that IGF-II is an embryonal mitogen (37-
40) and is thought to play an important
role in lung differentiation and maturation
(41). Transcription of the IGF-II gene in
the fetus is driven by three distinct
promoters (42-44) and yields three major
transcripts of 6.0 kb, 4.8 kb, and 1.9 kb
(45). In adult tissues, including the lung,
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Fig. 5. IGF-II gene expression in SCLC and NSCLC cell lines detected using the 1.1 -kb phigf-II cDNA
probe and Northern blot analysis (panel a). Each track contains approximately 5 ng mRNA, and filters were
exposed for 10 days. Panel b shows the actin signal for each track.
all three promoters are markedly sup-
pressed (42,43,45). Hence, in the present
study, the detection of abundant 6.0-kb
and 4.8-kb mRNA species in lung tumor
cells may represent re-activation of IGF-
II fetal promoters during lung carcino-
genesis. Recent circumstantial evidence
has also implicated IGF-II in the genesis
of developmental tumors, such as hepa-
toblastoma, Wilms' tumor, and rhabdo-
myosarcoma (45), but elevated ex-
pression is also seen in hepatocellular
carcinoma (46), colon carcinoma (47),
liposarcoma (47), and fibrosarcoma (48).
The IGF-II gene has been assigned to
Ilpl4.1 (49) and is in the immediate
vicinity of the Wilms' tumor suscep-
tibility gene locus. In the Wilms' tumor,
increased expression of the IGF-II gene is
thought to arise either through juxtaposi-
tion of the Wilms' tumor locus and the
IGF-II gene via chromosomal deletion or
through re-activation of a set of em-
bryonic genes, which includes the IGF-II
gene, as a consequence of the recessive
mutation in the Wilms' tumor locus (45).
Since chromosome 1 lp is one of several
sites of frequent cytogenetic deletion and
loss of heterozyosity in lung cancers
(50£l), it is tempting to speculate that
similar mechanisms may be responsible
for re-expression of the IGF-II gene in
lung tumors. Studies are in progress to in-
vestigate this possibility.
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Induction by Estrogen
Metabolite 16a-Hydroxyestrone
of Genotoxic Damage and
Aberrant Proliferation in
Mouse Mammary Epithelial
Cells
Nitin T. Telang* Akihiko Suto,
George Y. Wong, Michael P.
Osborne, H. Leon Bradlow
Background: Estrogens are potent
mammary tumor promoters influenc-
ing post-initiational events via epige-
netic mechanisms. The upregulation
(i.e., induction) of the C16a-hydroxyla-
tion pathway during 17(3-estradiol (E2)
biotransformation has been associated
with mammary cell transformation. The
action of E2 metabolites on tumorigenic
transformation, however, is poorly un-
derstood. Purpose: The newly estab-
lished mammary epithelial cell line
C57/MG, derived from the C57BL
mouse strain, was used to examine
whether E2 or its metabolites, 16-
hydroxyestrone (16a-OHE|) and estriol
(£_,), function as initiators of mammary
cell transformation. Methods: DNA
repair (hydroxyurea-insensitive thymi-
dine uptake), estrogen metabolism (3H
exchange to form 3H20), hyperprolifer-
ation (increased cell number), and ac-
quisition of anchorage-independent
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